MacroGenics Inc (MGNX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $140.60M
Last updated: Nov 17, 2026 at 11:06 AM ET
MacroGenics Inc (MGNX) Competitors
The companies most similar to MacroGenics are Genelux Corporation Common Stock (GNLX), enGene Therapeutics (ENGN) and Invivyd (IVVD). By market cap, MacroGenics ranks 7th of the 13 companies on this page; Greenwich Lifesciences (GLSI) is the largest at $219.29M.
Peer Comparison
MGNX's revenue growth of -64.8% is below the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| MacroGenics (MGNX) | $140.60M | N/A | 1.2x | -36.6% | -108.7% | -64.8% | 0.00% |
| Genelux Corporation Common Stock (GNLX) | $84.38M | N/A | N/A | 0.0% | N/A | -95.3% | 0.00% |
| enGene Therapeutics Inc. (ENGN) | $161.51M | N/A | N/A | 0.0% | -42.2% | 0.0% | 0.00% |
| Invivyd Inc. (IVVD) | $171.58M | N/A | 2.9x | -183.9% | N/A | 21.2% | 0.00% |
| Immunic Inc (IMUX) | $102.61M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Innate Pharma (IPHA) | $154.15M | N/A | 17.6x | 0.0% | 489.8% | 16.5% | 0.00% |
| Molecular Partners AG ADR (MOLN) | $112.71M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Anixa Biosciences Inc (ANIX) | $91.08M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Pmv Pharmaceuticals Inc (PMVP) | $95.93M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| NeOnc Technologies Holdings, Inc. Common Stock (NTHI) | $141.66M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Pyxis Oncology Inc (PYXS) | $188.98M | N/A | 11.6x | 0.0% | N/A | 0.0% | 0.00% |
| Greenwich Lifesciences Inc (GLSI) | $219.29M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Compass Therapeutics Inc. (CMPX) | $139.35M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $140.50M | N/A | 11.6x | 0.0% | 223.8% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to MacroGenics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Genelux Corporation Common Stock (GNLX) | Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering... | GNLX competitors |
| enGene Therapeutics Inc. (ENGN) | enGene Holdings Inc., through its subsidiary enGene, Inc., is a clinical-stage biotechnology company that develops genetic medicines through the delivery... | ENGN competitors |
| Invivyd Inc. (IVVD) | Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery... | IVVD competitors |
| Immunic Inc (IMUX) | Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune... | IMUX competitors |
| Innate Pharma (IPHA) | Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France... | |
| Molecular Partners AG ADR (MOLN) | Molecular Partners AG is a clinical-stage biopharmaceutical company. The company is headquartered in Schlieren, Switzerland. | MOLN competitors |
| Anixa Biosciences Inc (ANIX) | Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. | ANIX competitors |
| Pmv Pharmaceuticals Inc (PMVP) | PMV Pharmaceuticals, Inc., a precision oncology company, is dedicated to the discovery and development of small molecule tumor agnostic therapies for p53... | PMVP competitors |
| NeOnc Technologies Holdings, Inc. Common Stock (NTHI) | NeOnc Technologies Holdings, Inc. is a pioneering biotechnology firm dedicated to revolutionizing cancer treatment through its advanced immunotherapy... | NTHI competitors |
| Pyxis Oncology Inc (PYXS) | Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb)... | PYXS competitors |
| Greenwich Lifesciences Inc (GLSI) | Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for breast and other HER2 /... | GLSI competitors |
| Compass Therapeutics Inc. (CMPX) | Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple... | CMPX competitors |
Frequently Asked Questions About MGNX
Who are MacroGenics' main competitors?
The companies most similar to MacroGenics include Genelux Corporation Common Stock (GNLX), enGene Therapeutics (ENGN), Invivyd (IVVD), Immunic (IMUX) and Innate Pharma (IPHA), listed from the closest match.
Who is MacroGenics' biggest competitor?
Greenwich Lifesciences (GLSI) is the largest of the similar companies at $219.29M; Genelux Corporation Common Stock (GNLX) is the closest match by business profile, size, sector and industry.
How does MGNX stock compare with its competitors?
MGNX's P/S is 1.2x against a peer median of 11.6x; its net margin is -36.6% against a peer median of 0.0%.
Which of MacroGenics' competitors pays a higher dividend?
MacroGenics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is MacroGenics bigger than its competitors?
No. MacroGenics is 7th by market cap among the 13 companies on this page; the largest is Greenwich Lifesciences (GLSI) at $219.29M.
MGNX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts